Tumor immunomodulation

Tumor immunomodulation refers to therapeutic strategies and biological processes that modify the immune environment within tumors to either stimulate anti-tumor immunity or reduce immune suppression. Such modulation can involve immune checkpoint inhibitors (that block negative regulators like CTLA-4 or PD-1/PD-L1 on T cells), cytokines (such as interleukin-2 to activate lymphocytes), oncolytic viruses, radiotherapy (which induces immunogenic tumor cell death), and a variety of immunomodulatory drugs. The aim is to shift the tumor microenvironment from immunosuppressive to immunostimulatory, enabling the immune system to recognize and destroy cancer cells. This field encompasses diverse molecular and cellular pathways and is a foundational concept in cancer immunotherapy, not a specific molecular target[1][3][4][5]. Key point: Tumor immunomodulation is a therapeutic approach or process, not a single molecule or receptor, and thus does not fit into canonical target listings such as receptors, enzymes, or genes.

Other names

Tumor immune modulationImmunomodulation of the tumor microenvironment

Immune checkpoint blockade (CTLA-4, PD-1/PD-L1 inhibitors reinvigorate T cell responses)[3] - Stimulation or inhibition of cytokine signaling to enhance or suppress immune activity[1][3][4] - Induction of immunogenic cell death in tumor cells to release tumor antigens and enhance immune recognition[1][4] - Modulation of suppressive cells or mediators within the tumor microenvironment